Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Current Drug Therapy

A practical guide for buprenorphine initiation in the primary care setting

Roberto León-Barriera, MD, Samantha Jayne Zwiebel, MD, MA and Vania Modesto-Lowe, MD, MPH
Cleveland Clinic Journal of Medicine September 2023, 90 (9) 557-564; DOI: https://doi.org/10.3949/ccjm.90a.23022
Roberto León-Barriera
Assistant Professor of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Samantha Jayne Zwiebel
Assistant Professor of Clinical Psychiatry, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vania Modesto-Lowe
Medical Director, Hartford Behavioral Health, Hartford, CT; Department of Psychiatry, University of Connecticut, Community Faculty, University of Connecticut, Farmington, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1

    Buprenorphine formulations and indications

    Generic name and administration routeBrand nameDose formulationsUS Food and Drug Administration indication
    Buprenorphine hydrochloride for intravenous or intramuscular administrationBuprenex injection0.3 mg/mLAcute moderate-to-severe pain
    Buprenorphine transdermal systemButrans5 μg/hour
    7.5 μg/hour
    10 μg/hour
    15 μg/hour
    20 μg/hour
    Chronic pain
    Buprenorphine buccal filmBelbuca75 μg
    150 μg
    300 μg
    450 μg
    600 μg
    750 μg
    900 μg
    Chronic pain
    Buprenorphine extended-release injection for subcutaneous useSublocade300 mg/1.5 mL monthly after induction for first 2 months
    100 mg/0.5 mL maintenance dose monthly (can increase to 300 mg)
    Opioid use disorder
    Buprenorphine sublingual tabletsSubutex2 mg
    8 mg
    Opioid use disorder
    Buprenorphine/naloxone sublingual filmSuboxone2 mg/0.5 mg
    4 mg/1 mg
    8 mg/2 mg
    12 mg/3 mg
    Opioid use disorder
    Buprenorphine/naloxone sublingual tabletsSuboxone2 mg/0.5 mg
    8 mg/2 mg
    Opioid use disorder
    Buprenorphine/naloxone sublingual rapid-dissolve tabletsZubsolv0.7 mg/0.18 mg
    1.4 mg/0.36 mg
    2.9 mg/0.71 mg
    5.7 mg/1.4 mg
    8.6 mg/2.1 mg
    11.4 mg/2.9 mg
    Opioid use disorder
    • Based on information in references 22 and 23.

    • View popup
    TABLE 2

    Options for home buprenorphine induction

    DayComplex home inductionSimplified home inductionPrecise induction (may be better suited for inpatient use)
    1Cut 2-mg buprenorphine/naloxone film into 4 pieces, take 1 piece every 6 hoursCut 8-mg buprenorphine/naloxone film into 8 pieces, take 1 piece every 1–2 hours150-μg buprenorphine buccal film every 3 hours for 8 doses
    2Cut 2-mg buprenorphine/naloxone film into 2 pieces, take 1 piece every 6 hoursTake 8-mg buprenorphine/naloxone film twice daily450-μg buprenorphine buccal film every 6 hours for 2 doses; then 900-μg buprenorphine buccal film for 2 doses
    3Take 2-mg buprenorphine/naloxone film every 6 hoursFollow up with primary care physician2-mg buprenorphine/naloxone film every 4 hours for 4 doses
    4Take 8-mg buprenorphine/naloxone film twice daily8-mg buprenorphine/naloxone film 2 or 3 times per day
    5Follow up with primary care physicianFollow up with primary care physician
    • Based on information in reference 36.

    • View popup
    TABLE 3

    Symptomatic management of opioid withdrawal

    SymptomDrugDose
    AnxietyHydroxyzine25–100 mg orally every 6–8 hours as needed (maximum 400 mg/day)
    Lorazepam1 mg every 4–6 hours as needed (maximum 6 mg/day)
    Hypertension, tachycardiaClonidine0.1–0.2 mg every 6–8 hours, taper if given for > 7 days
    DiarrheaLoperamide4 mg initial dose followed by 2 mg after each loose stool (maximum 16 mg/day)
    Myalgias, arthralgiasAcetaminophen1,000 mg every 6–8 hours
    Ibuprofen600 mg every 6 hours for up to 7 days (maximum 2,400 mg/day)
    Nausea, vomitingOndansetron4 mg every 6 hours as needed (maximum 16 mg/day)
    InsomniaTrazodone25–100 mg nightly (maximum 300 mg)
    Muscle crampsCyclobenzaprine5–10 mg every 8 hours as needed (maximum 30 mg/day)
    Gastrointestinal crampsDicyclomine10–20 mg every 6–8 hours as needed (maximum 160 mg/day)
    • Based on information in references 36, 39, and 40.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 90 (9)
Cleveland Clinic Journal of Medicine
Vol. 90, Issue 9
1 Sep 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A practical guide for buprenorphine initiation in the primary care setting
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A practical guide for buprenorphine initiation in the primary care setting
Roberto León-Barriera, Samantha Jayne Zwiebel, Vania Modesto-Lowe
Cleveland Clinic Journal of Medicine Sep 2023, 90 (9) 557-564; DOI: 10.3949/ccjm.90a.23022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A practical guide for buprenorphine initiation in the primary care setting
Roberto León-Barriera, Samantha Jayne Zwiebel, Vania Modesto-Lowe
Cleveland Clinic Journal of Medicine Sep 2023, 90 (9) 557-564; DOI: 10.3949/ccjm.90a.23022
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • SHOULD PRIMARY CARE CLINICIANS PRESCRIBE BUPRENORPHINE?
    • BUPRENORPHINE: PHARMACOLOGY AND FORMULATIONS
    • STANDARD BUPRENORPHINE INDUCTION: METHOD AND CHALLENGES
    • LOW-DOSE BUPRENORPHINE INDUCTION
    • TIPS FOR MANAGING PRECIPITATED WITHDRAWAL
    • TAKE-HOME MESSAGES
    • DISCLOSURES
    • Acknowledgments
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Reducing the risks when using benzodiazepines to treat insomnia: A public health approach
  • Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
Show more Current Drug Therapy

Similar Articles

Subjects

  • Drug Therapy
  • Mental Health
  • Pain

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire